Filing Flows

Filing Flows › Ultragenyx Pharmaceutical (RARE) › Next earnings date

Ultragenyx Pharmaceutical (RARE) earnings: missed the estimate

Ultragenyx Pharmaceutical (RARE) reported on Nov 3, 2026 and missed the EPS estimate: −$1.16 against −$0.75 (-54.4%). Revenue was $173M for Q3 2026, +8% year over year. It beat the EPS estimate in 20% of the quarters on record.

Last result−54.4% vs estimate
Beat rate20%

The last report

Ultragenyx Pharmaceutical reported revenue of $173M for the third quarter 2026 (+8% Y/Y), net loss $118M: Product $105M, Royalty $68.0M. How it makes money → · Every quarter →

Ultragenyx Pharmaceutical: EPS against the estimate, last 5 reportsUltragenyx Pharmaceutical: EPS against the estimate, last 5 reportsEstimateReported−$1.21−$1.81Nov 25−$1.17−$1.29Feb 26−$1.46−$1.54May 26−$1.00−$0.90Aug 26−$0.75−$1.16Nov 26
Latest (Nov 26): Estimate −$0.75, Reported −$1.16.
RARE: the stock's move on each reportRARE: the stock's move on each reportAug 4, 2026-0.4%May 5, 2026+4.5%Feb 12, 2026-14.1%Nov 4, 2025-4.8%

Ultragenyx Pharmaceutical's latest quarter

Ultragenyx Pharmaceutical, Q3 2026: revenue $173M (+8% year over year), operating margin -63.6%, net loss $118M, operating cash flow −$43.0M. The chart follows the revenue to costs, profit and cash.

Questions

Did Ultragenyx Pharmaceutical beat earnings?

Ultragenyx Pharmaceutical (RARE) reported on Nov 3, 2026 and missed the EPS estimate: −$1.16 against −$0.75 (-54.4%).

When does RARE report earnings?

The next date is not set yet.

Does Ultragenyx Pharmaceutical usually beat earnings?

It beat the consensus EPS estimate in 20% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.